Systematic review: Is the use of NSAIDs effective and safe in the elderly?;Revisión sistemática: ¿Es eficaz y seguro el uso de AINE para los ancianos?

Reumatologia Clinica

Volumn 4, Issue 5, 2008, Pages 172-182

  Loza, Estíbaliz ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Efficacy; Elderly; Non steroidal anti inflammatory drugs; Safety

Indexed keywords

CELECOXIB; DICLOFENAC; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PIROXICAM; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

ARTERIAL SYSTOLIC PRESSURE; ARTICLE; BLEEDING; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPEPSIA; EDEMA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HUMAN; JOINT STIFFNESS; MUSCULOSKELETAL PAIN; NEPHROTOXICITY; OSTEOARTHRITIS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SIDE EFFECT; STOMACH ULCER; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 54549087939     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/S1699-258X(08)72461-6     Document Type: Article

References (106)

1. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787-96.
2. Morgan GJ, Kaine J, DeLapp R, Palmer R. Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. J Clin Gastroenterol. 2001;32:310-4.
3. Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther. 2003;18:125-32.
4. Woodhouse KW, Wynne H. The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly. Clin Pharmacokinet. 1987;12:111-22.
5. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int. 1993;44:643-53.
6. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160:777-84.
7. Niccoli L, Bellino S, Cantini F. Renal tolerability of three commonly employed non-steroidal anti-inflammatory drugs in elderly patients with osteoarthritis. Clin Exp Rheumatol. 2002;20:201-7.
8. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials. 1996;17:1-12.
9. Detora LM, Krupa D, Bolognese J, Sperling RS, Ehrich EW. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. J Rheumatol. 2001;28:2494-503.
10. Eisen GM, Goldstein JL, Hanna DB, Rublee DA. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment Pharmacol Ther. 2005;21:591-8.
11. Lisse J, Espinoza L, Zhao SZ, Dedhiya SD, Osterhaus JT. Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. J Gerontol A Biol Sci Med Sci. 2001;56:M167-75.
12. Schiff M, Minic M. Comparison of the analgesic efficacy and safety of nonprescription doses of naproxen sodium and Ibuprofen in the treatment of osteoarthritis of the knee. J Rheumatol. 2004;31:1373-83.
13. Bakshi R, Darekar B, Langdon CG, Rotman H. Efficacy and tolerability of diclofenac dispersible in elderly patients with osteoarthritis. Curr Med Res Opin. 1991;12:459-65.
14. Chan FK, Hung LC, Suen BY, Wong VW, Hui AJ, Wu JC, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology. 2004;127:1038-43.
15. Earl RT, Jenkins R, Munro AJ. A double-masked comparison of the efficacy of once-daily sustained-release ibuprofen and once-daily piroxicam for 24-hour control of arthralgia due to osteoarthritis in the elderly. Curr Ther Res Clin Exp. 1996;57:811-21.
16. Hawkey CJ, Weinstein WM, Smalley W, Gitton X, Sallstig P, Stricker K, et al. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. Gastroenterology. 2007;133:57-64.
17. Hawkey CJ, Farkouh M, Gitton X, Ehrsam E, Huels J, Richardson P. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics. Aliment Pharmacol Ther. 2004;20:51-63.
18. Kaarela K, Lehtinen K, Skinhøj A, Andersen F. The effect of different indomethacin formulations in young and elderly patients: a comparative controlled clinical trial. Curr Med Res Opin. 1989;11:427-31.
19. Koch M, Dezi A, Tarquini M, Capurso L. Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Dig Liver Dis. 2000;32:138-51.
20. Regula J, Butruk E, Dekkers CP, De Boer SY, Raps D, Simon L, et al. Prevention of nsaid-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol. 2006;101:1747-55.
21. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-9.
22. Whelton A, White WB, Bello AE, Puma JA, Fort JG; SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959-63.
23. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91:213-22.
24. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol Suppl. 1989;83:21-7.
25. Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther. 1999;21:992-1003.
26. Admani AK, Verma S. A study of sulindac versus ibuprofen in elderly patients with osteoarthritis. Curr Med Res Opin. 1983;8:315-20.
27. Ahern MJ, Wetherall M, Leslie A, James RH, Roberts-Thomson PJ, Rennie GC. A comparison of ketoprofen SR and sulindac in the elderly with rheumatoid arthritis. Br J Clin Pract. 1992;46:229-33.
28. Arone S. Long term study of ketoprofen sr in elderly patients. Scand J Rheumatol Suppl. 1989;83:15-9.
29. Bacon PA. Safety profile of etodolac in the elderly population. Eur J Rheumatol Inflamm. 1994;14:19-22.
30. Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, et al. Aspirin and nsaid use in older women: effect on bone mineral density and fracture risk. J Bone Miner Res. 1996;11:29-35.
31. Blardi P, Gatti F, Auteri A, Di Perri T. Effectiveness and tolerability of nimesulide in the treatment of osteoarthritic elderly patients. Int J Tissue React. 1992;14:263-8.
32. Browning RC, Johson K. Reducing the dose of oral NSAIDs by use of Feldene Gel: an open study in elderly patients with osteoarthritis. Adv Ther. 1994;11:198-207.
33. Busson M. A long-term study of flurbiprofen in rheumatological disorders: I. Rheumatoid arthritis. J Int Med Res. 1986;14:1-6.
34. Busson M. A long-term study of flurbiprofen in rheumatological disorders: II. Osteoarthrosis. J Int Med Res. 1986;14:13-8.
35. Calin A. Safety profile of a sustained release formulation of etodolac in patients with rheumatoid arthritis and osteoarthritis. Adv Ther. 1993;10:1-8.
36. Caughey D, Waterworth RF. A study of the safety of tenoxicam in general practice. N Z Med J. 1989;102:582-3.
37. Cordaro CI, Sartini A, Celotti F. Efficacy and tolerance of naproxen instant suspension formulation: a post-marketing survey. J Int Med Res. 1988;16:157-65.
38. Cummings DM, Amadio P Jr, Nettler S, Freedman M. Office-based evaluation of renal function in elderly patients receiving nonsteroidal anti-inflammatory drugs. J Am Board Fam Pract. 1988;1:77-80.
39. Currie WJ, Vandenburg MJ, Janke PG, Diggins JB. Symptomatic osteoarthritis in the elderly: multicentre comparative study of sulindac and ibuprofen. Br J Clin Pract. 1984;38:176-81.
40. Davis P, Gareau J. Multicenter comparative study of tiaprofenic acid in the treatment of patients with rheumatic diseases. Curr Ther Res Clin Exp. 1987;42:916-21.
41. Dominick KL, Ahern FM, Gold CH, Heller DA. Gender differences in nsaid use among older adults with osteoarthritis. Ann Pharmacother. 2003;37:1566-71.
42. Dreiser RL, Benevelli DC. Long term tolerability profile of nimesulide in the treatment of osteoarthritis. Drugs. 1993;46 Suppl 1:270-4.
43. Famaey JP, Colinet E. A double-blind trial of ketoprofen in the treatment of osteoarthritis of the hip. Scand J Rheumatol Suppl. 1976;1976:129-32.
44. Fossaluzza V, Montagnani G. Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double-blind trial versus naproxen. J Int Med Res. 1989;17:295-303.
45. Fries JF. Assessing and understanding patient risk. Scand J Rheumatol Suppl. 1992;92:21-4.
46. Fries JF, Murtagh KN, Bennett M, Zatarain E, Lingala B, Bruce B. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004;50:2433-40.
47. Fullerton T, Sica DA, Blum RA. Evaluation of the renal protective effect of misoprostol in elderly, osteoarthritic patients at risk for nonsteroidal anti-inflammatory drug-induced renal dysfunction. J Clin Pharmacol. 1993;33:1225-32.
48. Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40:1873-8.
49. Geczy M, Peltier L, Wolbach R. Naproxen tolerability in the elderly: a summary report. J Rheumatol. 1987;14:348-54.
50. Girawan D, Abdurachman SA, Djumhana A, Roslia J, Pramudiyo R. Comparison of endoscopic gastric mucosa features after administration of piroxicam to meloxicam and their correlation with dyspepsia symptoms in elderly patient with knee osteoarthritis. Acta Med Indones. 2004;36:202-6.
51. Grace EM, Rosenfeld JM, Sweeney GD, Buchanan WW. The pharmacokinetics of isoxicam in elderly patients with rheumatoid arthritis. Curr Med Res Opin. 1987;10:580-91.
52. Grigor RR, Spitz PW, Furst D. Salicylate toxicity in elderly patients with rheumatoid arthritis. Journal J Rheumatol. 1987;14:60-6.
53. Halici F, Prada GI. Elderly patients with osteoarthritis: treatment with nonselective, nonsteroidial, antiinflammatory drugs, and the gastrointestinal consequences. Arch Gerontol Geriatr Suppl. 2002;8:165-70.
54. Hart FD, Boardman PL. Indomethacin and phenylbutazone: a comparison. Br Med J. 1965;2:1281-4.
55. Hart CB, Tempero KF, Sromovsky JA, Rhymer AR. 'Osmosin' (sodium indomethacin trihydrate) in the treatment of elderly patients with osteoarthritis. Curr Med Res Opin. 1983;8 Suppl 2:72-82.
56. Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E. Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther. 2001;15:1593-601.
57. Henry D, Page J, Whyte I, Nanra R, Hall C. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol. 1997;44:85-90.
58. Hochain P, Berkelmans I, Czernichow P, Duhamel C, Tranvouez JL, Lerebours E, et al. Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol. 1995;7:419-26.
59. Horackova M, Schuck O, Komers R, Charvat J, Teplan V, Kvapil M. Effect of rofecoxib on the glomerular filtration rate, proteinuria and the renin-angiotensin-aldosterone system in elderly subjects with chronic renal impairment. Int J Clin Pharmacol Ther. 2005;43:413-9.
60. Innes EH. Efficacy and tolerance of flurbiprofen in the elderly using liquid and tablet formulations. Curr Med Res Opin. 1977;5:122-6.
61. Jackson RE, Mitchell FN, Brindley DA. Safety evaluation of nabumetone in United States clinical trials. Am J Med. 1987;83:115-20.
62. Janke PG, Diggins JB, Currie WJ, Dasgupta PK, Glick EN, Sheikh NA, et al. A multi-centre study of sulindac versus naproxen in the treatment of elderly osteoarthritic patients. Pharmatherapeutica. 1984;3:663-7.
63. Johnson AG, Simons LA, Simons J, Friedlander Y, McCallum J. Nonsteroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. Br J Clin Pharmacol. 1993;35:455-9.
64. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology. 2002;123:1006-12.
65. Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005;118:1271-8.
66. Lane NE, Bauer DC, Nevitt MC, Pressman AR, Cummings SR. Aspirin and nonsteroidal antiinflammatory drug use in elderly women: effects on a marker of bone resorption. J Rheumatol. 1997;24:1132-6.
67. Layton D, Riley J, Wilton LV, Shakir SA. Safety profile of rofecoxib as used in general practice in england: results of a prescription-event monitoring study. Br J Clin Pharmacol. 2003;55:166-74.
68. Le Loet X, Dreiser RL, Le Gros V, Febvre N. Therapeutic equivalence of diclofenac sustained-released 75 mg tablets and diclofenac enteric-coated 50 mg tablets in the treatment of painful osteoarthritis. Int J Clin Pract. 1997;51:389-93.
69. Littman BH, Bjarnason D, Bryant G, Engelbrecht J, Cohen M, Mertz L, et al. Steroid sparing activity of tenidap in patients with polymyalgia rheumatica: a multicenter double blind randomized placebo controlled study. J Rheumatol. 1995;22:1097-103.
70. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002;325:624.
71. Mann JL, Evans TS. Gastrointestinal-related complications in a longterm care population taking nsaids versus cox-2 inhibitor therapy. Consult Pharm. 2004;19:602-13.
72. McNeil V. Nsaids - a double-edged sword. Hospital Pharmacy. 1993; 28:50; 53-5.
73. Meurice J. Treatment of osteoarthritis: a 3-month comparison between tiaprofenic acid and indomethacin. Curr Med Res Opin. 1983;8:295-301.
74. Montrone F, Petrillo M, Ardizzone S, Scaricabarozzi I, Scotti A, Caruso I, et al. Imidazole salicylate versus piroxicam in the treatment of arthrosis in elderly patients. A double-blind clinical and endoscopic trial. J Am Geriatr Soc. 1990;38:985-8.
75. Morgan GJ, Poland M, DeLapp RE. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Am J Med. 1993;95:S19-27.
76. Morton DJ, Barrett-Connor EL, Schneider DL. Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bernardo study. J Bone Miner Res. 1998;13:1924-31.
77. Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, et al. Temporal relationship between use of nsaids, including selective cox-2 inhibitors, and cardiovascular risk. Drug Saf. 2006;29:621-32.
78. Nesher G, Sonnenblick M, Dwolatzky T. Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients. J Rheumatol. 1995;22:713-6.
79. Nietert PJ, Ornstein SM, Dickerson LM, Rothenberg RJ. Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. Pharmacotherapy. 2003;23:1416-23.
80. O'Brien WM. Long-term efficacy and safety of tolmetin sodium in treatment of geriatric patients with rheumatoid arthritis and osteoarthritis: a retrospective study. J Clin Pharmacol. 1983;23:309-23.
81. Perpignano G, Bogliolo A, Puccetti L. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. Int J Clin Pharmacol Res. 1994;14:203-16.
82. Puccetti L, Ciompi ML. Evaluation of the effectiveness and safety of etodolac in prolonged treatment of active osteoarthritis. Int J Clin Pharmacol Res. 1991;11:143-58.
83. Rabenda V, Burlet N, Ethgen O, Raeman F, Belaiche J, Reginster JY. A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2005;64:688-93.
84. Rabenda V, Burlet N, Belaiche J, Raeman F, Richy F, Reginster J, et al. Determinants of gastro-protective drugs co-prescription during treatment with nonselective nsaids: a prospective survey of 2197 patients recruited in primary care. Osteoarthritis Cartilage. 2006;14:625-30.
85. Rahme E, Marentette MA, Kong SX, Lelorier J. Use of nsaids, cox-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum. 2002;47:595-602.
86. Rahme E, Nedjar H. Risks and benefits of cox-2 inhibitors vs non-selective nsaids: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology. 2007;46:435-8.
87. Rahme E, Barkun AN, Toubouti Y, Scalera A, Rochon S, Lelorier J. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? Arthritis Rheum. 2007;57:748-55.
88. Roth SH, Tindall EA, Jain AK, McMahon FG, April PA, Bockow BI, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med. 1993;153:2565-71.
89. Roth SH, Bennett RE, Caldron PH, Mitchell CS, Swenson CM. Endoscopic evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clin Drug Investig. 1995;9:171-9.
90. Scharf S, Kwiatek R, Ugoni A. NSAIDs and faecal blood loss in elderly patients with osteoarthritis: is plasma half-life relevant? Aust N Z J Med. 1998;28:436-9.
91. Schattenkirchner M. Long-term safety of ketoprofen in an elderly population of arthritic patients. Scand J Rheumatol Suppl. 1991;91:27-36.
92. Schattenkirchner M. The safety profile of sustained-release etodolac. Rheumatol Int. 1993;13 Suppl 2:S31-5.
93. Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther. 2005;27:64-77.
94. Sheridan R, Montgomery AA, Fahey T. Nsaid use and bp in treated hypertensives: a retrospective controlled observational study. J Hum Hypertens. 2005;19:445-50.
95. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 1995;141:539-45.
96. Sontag SJ, Schnell TG, Budiman-Mak E, Adelman K, Fleischmann R, Cohen S, et al. Healing of NSAID-induced gastric ulcers with a synthetic prostaglandin analog (enprostil). Am J Gastroenterol. 1994;89:1014-20.
97. Stewart I, Thomas A. Mefenamic acid compared with diclofenac sodium in elderly patients with osteoarthritis. Br J Clin Pract. 1988;42:316-20.
98. Theiler R, Bischoff HA, Good M, Uebelhart D. Rofecoxib improves quality of life in patients with hip or knee osteoarthritis. Swiss Med Wkly. 2002;132:566-73.
99. Todesco S, Del Ross T, Marigliano V, Ariani A. Efficacy and tolerability of etodolac in aged patients affected by degenerative joint disease (osteoarthritis) in its active phase. Int J Clin Pharmacol Res. 1994;14:11-26.
100. Truitt KE, Sperling RS, Ettinger WH Jr, Greenwald M, DeTora L, Zeng Q, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano). 2001;13:112-21.
101. Vetter G. A comparison of naproxen and diclofenac sodium in the treatment of osteoarthritis in elderly patients. Br J Clin Pract. 1985;39:276-81.
102. Vonkeman HE, Fernandes RW, Van der Palen J, Van Roon EN, Van de Laar MA. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to nonsteroidal anti-inflammatory drugs: a nested case-control study. Arthritis Res Ther. 2007;9:R52.
103. Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int. 2006;70:1495-502.
104. Williams PI. Adverse effects of isoxicam in relation to age. Am J Med. 1985;79:38-40.
105. Williams PI, Hosie J, Scott DL. Etodolac therapy for osteoarthritis: a double-blind, placebo-controlled trial. Curr Med Res Opin. 1989;11:463-70.
106. Yajima H, Yamao J, Fukui H, Takakura Y. Up-to-date information on gastric mucosal lesions from long-term NSAID therapy in orthopedic outpatients: a study using logistic regression analysis. J Orthop Sci. 2007;12:341-6.